Global Thrombosis Drugs Markets, 2019-2023, with Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, and Sanofi Dominating

| Source: Research and Markets Research and Markets

Dublin, Dec. 18, 2018 (GLOBE NEWSWIRE) -- The "Global Thrombosis Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The thrombosis drugs market will register a CAGR of more than 9% by 2023.

Sedentary lifestyle is resulting in an increase in the number of thrombosis cases. The increase in sedentary lifestyle is leading to the rise in the prevalence of obesity across the world, thus increasing the risk of thrombosis.

Growing awareness of cardiac care

The increasing awareness of cardiac care is leading to the early diagnosis of various cardiac diseases. Various awareness camps have been organized by the governments and non-government organizations across the world to increase the awareness of heart health among the population.

Strong side-effects of anticoagulants

Anticoagulants or blood thinners are medications that are developed to dissolve blood clots in the body. Blood thinners have high efficacy. However, the side effects associated with the use of these drugs to treat thrombosis are high.

With the presence of a considerable number of companies, this market appears to be concentrated and with all companies constantly focusing improving their market positions, the competitive environment among the players is quite intense. The market is witnessing the entry of various generic drug manufacturing companies that are coming up with generic versions of the drugs.

Key Players

  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • DAIICHI SANKYO
  • Johnson & Johnson
  • Sanofi

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

PART 05: FIVE FORCES ANALYSIS

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY INDICATION

  • Market segmentation by indication
  • Comparison by indication
  • Pulmonary embolism - Market size and forecast 2018-2023
  • DVT - Market size and forecast 2018-2023
  • Market opportunity by indication

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • DAIICHI SANKYO
  • Johnson & Johnson
  • Sanofi

For more information about this report visit https://www.researchandmarkets.com/research/nfsh3w/global_thrombosis?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.


            











    

        

        
Contact Data